Clinical Trials Directory

Trials / Completed

CompletedNCT00441740

Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer

Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine as First Line Treatment in Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC). A Prospective , Multicenter, Randomized, Phase III Trial

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
419 (actual)
Sponsor
Hellenic Oncology Research Group · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate whether the gemcitabine/vinorelbine combination versus the gemcitabine/docetaxel combination as first line treatment, offers a survival advantage in patients with locally advanced/metastatic NSCLC.

Detailed description

Cisplatin-based chemotherapy represented the backbone of treatment of advanced NSCLC. However, several trials comparing platinum versus non-platinum based chemotherapy regimens failed to demonstrate a statistically significant difference in terms of time to tumor progression or survival. Newer agents such as gemcitabine, docetaxel and vinorelbine have shown significant activity in the treatment of NSCLC. Gemcitabine/vinorelbine combination as first line treatment has demonstrated a response rate (RR) of 18-43% and a median overall survival (OS) of 9.8-13 months. Similarly, the gemcitabine/docetaxel combination has shown a RR 32-35% and a median OS of 9-12 months. Given their proven efficacy, the combination of these two doublets, would be interesting.

Conditions

Interventions

TypeNameDescription
DRUGVinorelbineVinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
DRUGGemcitabineGemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
DRUGDocetaxelDocetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
DRUGGemcitabineGemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles

Timeline

Start date
2004-04-01
Primary completion
2008-02-01
Completion
2008-02-01
First posted
2007-03-01
Last updated
2008-10-31

Locations

9 sites across 1 country: Greece

Source: ClinicalTrials.gov record NCT00441740. Inclusion in this directory is not an endorsement.